Caliway Biopharmaceuticals Co Ltd
TTWSE:691973.80
TWD
-2.20
(-2.89%)
ISIN
TW0006919004
Return %
Stock
S&P 500
1Y
-55.14
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yu Fang Ling
- Full Time Employees
- 20
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No.99, Xintai 5th Road New Taipei City TP Taiwan 221
- IPO Date
- Oct 2, 2024
- Website
- caliwaybiopharma.com
- Similar Companies
- Business
- Caliway Biopharmaceuticals Co., Ltd. (TWSE:6919) develops small-molecule therapeutics for medical aesthetics and inflammatory diseases. The company, founded in 2012 and headquartered in New Taipei City, Taiwan, focuses on unmet needs in areas such as non-surgical fat reduction, cellulite, hyperpigmentation, skin aging, Dercum's disease, osteoarthritis, and central obesity; its lead product, CBL-514, is a first-in-class injectable that induces targeted adipocyte apoptosis for subcutaneous fat reduction, cellulite treatment, and Dercum's disease, currently advancing through global Phase 3 trials including SUPREME-01; CBL-539 comprises a long-acting injectable for refractory melasma via melanin inhibition and skin elasticity improvement through collagen production; CBF-520 targets central obesity in preclinical development; the company also pursues combination therapies with GLP-1 receptor agonists for weight rebound management and offers dietary supplements. Caliway operates primarily in the biotechnology sector, targeting global markets with high-potential indications exceeding $10 billion in value, and plans regional authorizations in Taiwan, China, Korea, and Southeast Asia alongside global licensing partnerships. Recent developments include FDA clearance and IND approval for the SUPREME-01 Phase 3 study of CBL-514 in July 2025, Health Canada approval for the same trial in August 2025 with U.S.-Canada recruitment underway, inclusion in the MSCI Global Standard Index effective August 2025, successful End-of-Phase 2 meeting with FDA in May 2025 confirming pivotal design for abdominal fat reduction NDA, positive Phase 2 cellulite results in 2024 with over 95% improvement rates, and preclinical data presentations on CBL-514-GLP-1 combinations at EASD 2025 and BIO 2025.